Systematic Review of the Clinical Outcomes of Iron Reduction in Hereditary Hemochromatosis
Anil Prabhu, Tamsin Cargill, Nia Roberts, John D. Ryan – 4 June 2020
The Tumor Microenvironment in Cholangiocarcinoma Progression
Luca Fabris, Keisaku Sato, Gianfranco Alpini, Mario Strazzabosco – 4 June 2020
Acyl‐Coenzyme A Thioesterase 9 Traffics Mitochondrial Short‐Chain Fatty Acids Toward De Novo Lipogenesis and Glucose Production in the Liver
Sandra Steensels, Jixuan Qiao, Yanzhen Zhang, Kristal M. Maner‐Smith, Nourhan Kika, Corey D. Holman, Kathleen E. Corey, W. Clay Bracken, Eric A. Ortlund, Baran A. Ersoy – 4 June 2020
Letter to the Editor: Sodium‐Glucose Cotransporter‐2 Inhibitors Are Not the Magic Pills for Control of Ascites in Cirrhosis and Diabetes
Karan Kumar, Anand Kulkarni – 3 June 2020
Identifying an Optimal Liver Frailty Index Cutoff to Predict Waitlist Mortality in Liver Transplant Candidates
Ani Kardashian, Jin Ge, Charles E. McCulloch, Matthew R. Kappus, Michael A. Dunn, Andres Duarte‐Rojo, Michael L. Volk, Robert S. Rahimi, Elizabeth C. Verna, Daniel R. Ganger, Daniela Ladner, Jennifer L. Dodge, Brian Boyarsky, Mara McAdams‐DeMarco, Dorry L. Segev, Jennifer C. Lai – 3 June 2020
Letter to the Editor: Sodium‐Glucose Cotransporter 2 Inhibitors Ameliorate Ascites and Peripheral Edema in Patients With Cirrhosis and Diabetes
Dimitrios Patoulias, Alexandra Katsimardou, Christodoulos Papadopoulos, Michael Doumas – 3 June 2020
Reply
Keyur Patel, Chuhan Chung, Robert P. Myers – 3 June 2020
Severe Refractory Checkpoint Inhibitor‐Related Hepatitis Reversed With Anti‐Thymocyte Globulin and n‐Acetylcysteine
Douglas Motomura, Tara Baetz, Andrea Grin, Jennifer A. Flemming – 2 June 2020
Lack of Augmenter of Liver Regeneration Disrupts Cholesterol Homeostasis of Liver in Mice by Inhibiting the AMPK Pathway
Xin Wang, Ling‐yue Dong, Qu‐jing Gai, Wei‐lun Ai, Yuan Wu, Wei‐chun Xiao, Jing Zhang, Wei An – 2 June 2020 – It is well known that excessive cholesterol accumulation within hepatocytes deteriorates nonalcoholic fatty liver disease (NAFLD). Augmenter of liver regeneration (ALR) has been reported to alleviate NAFLD through anti‐apoptosis; however, whether ALR could protect liver from cholesterol‐induced NAFLD remains unclear.
Is Portal Inflow Modulation Always Necessary for Successful Utilization of Small Volume Living Donor Liver Grafts?
Sami Akbulut, Tevfik Tolga Sahin, Cemalettin Koc, Sezai Yilmaz – 2 June 2020